208 related articles for article (PubMed ID: 20186771)
1. Characterization of formulation parameters affecting low molecular weight drug release from in situ forming drug delivery systems.
Patel RB; Carlson AN; Solorio L; Exner AA
J Biomed Mater Res A; 2010 Aug; 94(2):476-84. PubMed ID: 20186771
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive characterization of the effect of varying PLGA molecular weight blends on in situ forming implant behavior using ultrasound imaging.
Solorio L; Olear AM; Hamilton JI; Patel RB; Beiswenger AC; Wallace JE; Zhou H; Exner AA
Theranostics; 2012; 2(11):1064-77. PubMed ID: 23227123
[TBL] [Abstract][Full Text] [Related]
3. Effect of injection site on in situ implant formation and drug release in vivo.
Patel RB; Solorio L; Wu H; Krupka T; Exner AA
J Control Release; 2010 Nov; 147(3):350-8. PubMed ID: 20728486
[TBL] [Abstract][Full Text] [Related]
4. Development of a sustained-release system for perivascular delivery of dipyridamole.
Zhu W; Masaki T; Bae YH; Rathi R; Cheung AK; Kern SE
J Biomed Mater Res B Appl Biomater; 2006 Apr; 77(1):135-43. PubMed ID: 16206204
[TBL] [Abstract][Full Text] [Related]
5. Effect of formulation parameters on 2-methoxyestradiol release from injectable cylindrical poly(DL-lactide-co-glycolide) implants.
Desai KG; Mallery SR; Schwendeman SP
Eur J Pharm Biopharm; 2008 Sep; 70(1):187-98. PubMed ID: 18472254
[TBL] [Abstract][Full Text] [Related]
6. Co-effect of aqueous solubility of drugs and glycolide monomer on in vitro release rates from poly(D,L-lactide-co-glycolide) discs and polymer degradation.
Kim JM; Seo KS; Jeong YK; Hai BL; Kim YS; Khang G
J Biomater Sci Polym Ed; 2005; 16(8):991-1007. PubMed ID: 16128233
[TBL] [Abstract][Full Text] [Related]
7. Formulation and characterization of injectable poly(DL-lactide-co-glycolide) implants loaded with N-acetylcysteine, a MMP inhibitor.
Desai KG; Mallery SR; Schwendeman SP
Pharm Res; 2008 Mar; 25(3):586-97. PubMed ID: 17891553
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo study of thymosin alpha1 biodegradable in situ forming poly(lactide-co-glycolide) implants.
Liu Q; Zhang H; Zhou G; Xie S; Zou H; Yu Y; Li G; Sun D; Zhang G; Lu Y; Zhong Y
Int J Pharm; 2010 Sep; 397(1-2):122-9. PubMed ID: 20650309
[TBL] [Abstract][Full Text] [Related]
9. Concomitant monitoring of implant formation and drug release of in situ forming poly (lactide-co-glycolide acid) implants in a hydrogel matrix mimicking the subcutis using UV-vis imaging.
Sun Y; Jensen H; Petersen NJ; Larsen SW; Østergaard J
J Pharm Biomed Anal; 2018 Feb; 150():95-106. PubMed ID: 29216591
[TBL] [Abstract][Full Text] [Related]
10. Development of chondroitin sulfate encapsulated PLGA microsphere delivery systems with controllable multiple burst releases for treating osteoarthritis.
Jiang T; Petersen RR; Call G; Ofek G; Gao J; Yao JQ
J Biomed Mater Res B Appl Biomater; 2011 May; 97(2):355-63. PubMed ID: 21442745
[TBL] [Abstract][Full Text] [Related]
11. Size effect of PLGA spheres on drug loading efficiency and release profiles.
Dawes GJ; Fratila-Apachitei LE; Mulia K; Apachitei I; Witkamp GJ; Duszczyk J
J Mater Sci Mater Med; 2009 May; 20(5):1089-94. PubMed ID: 19160026
[TBL] [Abstract][Full Text] [Related]
12. Possibilities of poly(D,L-lactide-co-glycolide) in the formulation of nanomedicines against cancer.
Holgado MA; Alvarez-Fuentes J; Fernández-Arévalo M; Arias JL
Curr Drug Targets; 2011 Jul; 12(8):1096-111. PubMed ID: 21443478
[TBL] [Abstract][Full Text] [Related]
13. Development of PLGA-based injectable delivery systems for hydrophobic fenretinide.
Wischke C; Zhang Y; Mittal S; Schwendeman SP
Pharm Res; 2010 Oct; 27(10):2063-74. PubMed ID: 20668921
[TBL] [Abstract][Full Text] [Related]
14. Enhanced surface attachment of protein-type targeting ligands to poly(lactide-co-glycolide) nanoparticles using variable expression of polymeric acid functionality.
McCarron PA; Marouf WM; Donnelly RF; Scott C
J Biomed Mater Res A; 2008 Dec; 87(4):873-84. PubMed ID: 18228271
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of poly (ϵ-caprolactone-co-DL-lactide) as a biodegradable material for in situ forming implants: evaluation of drug release and in vivo degradation.
Zhang X; Zhang C; Zhang W; Meng S; Liu D; Wang P; Guo J; Li J; Guan Y; Yang D
Drug Dev Ind Pharm; 2015 Feb; 41(2):342-52. PubMed ID: 24320881
[TBL] [Abstract][Full Text] [Related]
16. Phase inversion dynamics of PLGA solutions related to drug delivery. Part II. The role of solution thermodynamics and bath-side mass transfer.
Brodbeck KJ; DesNoyer JR; McHugh AJ
J Control Release; 1999 Dec; 62(3):333-44. PubMed ID: 10528071
[TBL] [Abstract][Full Text] [Related]
17. Fabrication and characterization of permeable degradable poly(DL-lactide-co-glycolide) (PLGA) hollow fiber phase inversion membranes for use as nerve tract guidance channels.
Wen X; Tresco PA
Biomaterials; 2006 Jul; 27(20):3800-9. PubMed ID: 16564567
[TBL] [Abstract][Full Text] [Related]
18. Improving release completeness from PLGA-based implants for the acid-labile model protein ovalbumin.
Duque L; Körber M; Bodmeier R
Int J Pharm; 2018 Mar; 538(1-2):139-146. PubMed ID: 29355654
[TBL] [Abstract][Full Text] [Related]
19. PLGA in situ implants formed by phase inversion: critical physicochemical parameters to modulate drug release.
Parent M; Nouvel C; Koerber M; Sapin A; Maincent P; Boudier A
J Control Release; 2013 Nov; 172(1):292-304. PubMed ID: 24001947
[TBL] [Abstract][Full Text] [Related]
20. Delivery of radix ophiopogonis polysaccharide via sucrose acetateisobutyrate-based in situ forming systems alone or combined with itsmono-PEGylation.
Wang L; Zheng X; Wu F; Shen L; Lin X; Feng Y
Drug Deliv; 2018 Nov; 25(1):267-277. PubMed ID: 29334805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
